Heide L. Ford

10.1k citations

91 papers · 6.2k indexed · 1 hit paper · h-index 44

Impact in

Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Oncology top 1%
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways

Papers in

Oncology 41
- Cancer Cells and Metastasis 26
- Cancer-related Molecular Pathways 18
Cancer Research 20
- MicroRNA in disease regulation 6

Co-authors: Douglas S. Micalizzi Susan M. Farabaugh Paul Jedlicka Andrew Thorburn Kian Behbakht David Drasin Tyler P. Robin Ricardo D. Coletta
Journals: Cancer Research (16 papers)Oncogene (7 papers)Journal of Biological Chemistry (5 papers)Proceedings of the National Academy of Sciences (5 papers)Nature Communications (4 papers)
Partner nations: United States Brazil China

In The Last Decade

Heide L. Ford

88 papers receiving 6.1k citations

Hit Papers

align trajectories log scale

Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression 2010 · 765 citations

Peers

Countries citing papers authored by Heide L. Ford

Since Specialization

Citations

This map shows the geographic impact of Heide L. Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heide L. Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heide L. Ford more than expected).

Fields of papers citing papers by Heide L. Ford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heide L. Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heide L. Ford. The network helps show where Heide L. Ford may publish in the future.

Co-authors

The 25 scholars most cited alongside Heide L. Ford, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Heide L. Ford Line = papers co-authored together Heide L. Ford links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Lineage Tracing and Single-Cell RNA Sequencing Reveal a Common Transcriptional State in Breast Cancer Tumor–Initiating Cells Characterized by IFN/STAT1 Activity Cancer Research ·P. YA. BAKUS, López-Correa Rh, John D. Landua, 潘文亭, R. T., Lacey E. Dobrolecki, Media Fitri, Xingxin Pan, HU Tingze, الهام مقدمنیا, S. Stephen Yi, Heide L. Ford, Michael T. Lewis	2025	0
2	EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis Science Advances ·Sheera R. Rosenbaum, Anıl Gök, Jill Jepson, Media Fitri, Annika Gustafson, 小松孔明, Eduard Krebs, 宮田徹, Nicholas Turner, Etienne Danis, Christopher C. Ebmeier, Nicole S. Spoelstra, Jennifer K. Richer, Paul Jedlicka, James C. Costello, Rui Zhao, Heide L. Ford	2025	2
3	Cryo-EM structures reveal the PP2A–B55α and Eya3 interaction that can be disrupted by a peptide inhibitor Journal of Biological Chemistry ·Shasha Shi, Xueni Li, Christopher P Alderman, Н. С. Габбасов, Wei Huang, 王俊玮, Lingdi Zhang, John J. Rossi, Jorge Gaona-Bernal, بوشمة الهادي, Hong Zheng, Derek J. Taylor, Heide L. Ford, Rui Zhao	2025	1
4	SIX2 Mediates Late-Stage Metastasis via Direct Regulation of SOX2 and Induction of a Cancer Stem Cell Program Cancer Research ·Michael Oliphant, Yu. V. Maslennikova, Matthew D. Galbraith, Ahwan Pandey, Vadym Zaberezhnyy, Pratyaydipta Rudra, Martha Peck, James C. Costello, Debashis Ghosh, James DeGregori, Joaquı́n M. Espinosa, Heide L. Ford	2019	34
5	Eya3 promotes breast tumor–associated immune suppression via threonine phosphatase–mediated PD-L1 upregulation Journal of Clinical Investigation ·Rebecca L. Vartuli, Hengbo Zhou, Lingdi Zhang, Rani K. Powers, Jared Klarquist, Pratyaydipta Rudra, Yu. V. Maslennikova, Debashis Ghosh, James C. Costello, Ross M. Kedl, Jill E. Slansky, Rui Zhao, Heide L. Ford	2018	34
6	A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance Molecular Cancer Research ·Lina Y. Dimberg, Christina G. Towers, Kian Behbakht, Edward J. Van Lierr, Jihye Kim, Susan Fosmire, Christopher C. Porter, Aik Choon Tan, Andrew Thorburn, Heide L. Ford	2017	6
7	Negative regulation of Endothelin signaling by SIX1 is required for proper maxillary development Development ·André L. P. Tavares, Timothy C. Cox, 박미지, Heide L. Ford, David E. Clouthier	2017	32
8	TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation Cancer Research ·David Drasin, Anna L. Guarnieri, Deepika Neelakantan, Jihye Kim, Sue Illman, Chu-An Wang, Vadym Zaberezhnyy, Pierluigi Gasparini, Luciano Cascione, Kay Huebner, Aik Choon Tan, Heide L. Ford	2015	49
9	Homeoprotein Six2 Promotes Breast Cancer Metastasis via Transcriptional and Epigenetic Control of E-Cadherin Expression Cancer Research ·Chu-An Wang, David Drasin, J. Rodrigues Maria, Paul Jedlicka, Vadym Zaberezhnyy, Michelle A. Guney, Howard Li, Raphael A. Nemenoff, James C. Costello, Aik Choon Tan, Heide L. Ford	2014	45
10	Epithelial–Mesenchymal Transition and Tumor Suppression Are Controlled by a Reciprocal Feedback Loop between ZEB1 and Grainyhead-like-2 Cancer Research ·Benjamin Cieply, Joshua C. Farris, James Denvir, Heide L. Ford, Steven M. Frisch	2013	151
11	EWS/FLI1 Regulates EYA3 in Ewing Sarcoma via Modulation of miRNA-708, Resulting in Increased Cell Survival and Chemoresistance Molecular Cancer Research ·Tyler P. Robin, Anna Smith, Fuxiu Liu, 忠行村上, Paul Jedlicka, Heide L. Ford	2012	73
12	Distinct TRAIL Resistance Mechanisms Can Be Overcome by Proteasome Inhibition but not Generally by Synergizing Agents Cancer Research ·力渋谷, Lianghua Bin, Jacqueline Thorburn, Kian Behbakht, Heide L. Ford, Andrew Thorburn	2011	27
13	Homeoprotein Six1 Increases TGF-β Type I Receptor and Converts TGF-β Signaling from Suppressive to Supportive for Tumor Growth Cancer Research ·Douglas S. Micalizzi, Chu-An Wang, Susan M. Farabaugh, William P. Schiemann, Heide L. Ford	2010	92
14	Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression Journal of Mammary Gland Biology and Neoplasia ·Douglas S. Micalizzi, Susan M. Farabaugh, Heide L. Ford Hit paper breakdown →	2010	765
15	The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling Journal of Clinical Investigation ·Douglas S. Micalizzi, Kimberly Christensen, Paul Jedlicka, Ricardo D. Coletta, Anna E. Barón, J. Chuck Harrell, Kathryn B. Horwitz, Dean Billheimer, Karen A. Heichman, Alana L. Welm, William P. Schiemann, Heide L. Ford	2009	196
16	Six1 Overexpression in Mammary Cells Induces Genomic Instability and Is Sufficient for Malignant Transformation Cancer Research ·Ricardo D. Coletta, Kimberly Christensen, Douglas S. Micalizzi, Paul Jedlicka, Marileila Varella‐Garcia, Heide L. Ford	2008	84
17	TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them Drug Resistance Updates ·Andrew Thorburn, Kian Behbakht, Heide L. Ford	2008	139
18	Six1 Overexpression in Ovarian Carcinoma Causes Resistance to TRAIL-Mediated Apoptosis and Is Associated with Poor Survival Cancer Research ·Kian Behbakht, Lubna Qamar, Johnny Chin Fui Chung, Ricardo D. Coletta, Susan A. Davidson, Andrew Thorburn, Heide L. Ford	2007	148
19	Characterization of two avian MHC-like genes reveals an ancient origin of the CD1 family Proceedings of the National Academy of Sciences ·Marcia M. Miller, Д.И. Коломацкий, Emilio Parisini, Ricardo D. Coletta, Ronald M. Goto, Stella Y. Lee, Duarte C. Barral, Huei‐Shyong Wang, Carme Roura‐Mir, Heide L. Ford, Michael B. Brenner, Christopher C. Dascher	2005	84
20	Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. PubMed ·Rong Guan, Heide L. Ford, Yineng Fu, Youzhi Li, (unknown), Arthur B. Pardee	2000	274

About Heide L. Ford

Heide L. Ford is a scholar working on Oncology, Cancer Research, Molecular Biology, Immunology and Biotechnology, having authored 91 papers that have together received 6.2k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (26 papers), Cancer-related Molecular Pathways (18 papers), Ubiquitin and proteasome pathways (15 papers), Epigenetics and DNA Methylation (12 papers), Developmental Biology and Gene Regulation (9 papers), Cancer-related gene regulation (8 papers), Renal and related cancers (8 papers) and MicroRNA in disease regulation (6 papers). The work is most often cited by research in Cancer Research (1.6k citations), Oncology (2.2k citations), Molecular Biology (4.7k citations), Cell Biology (570 citations) and Immunology (608 citations). Heide L. Ford has collaborated with scholars based in United States, Brazil and China. Frequent co-authors include Douglas S. Micalizzi, Susan M. Farabaugh, Paul Jedlicka, Andrew Thorburn, Kian Behbakht, David Drasin, Tyler P. Robin, Ricardo D. Coletta, Arthur B. Pardee and Aaron Patrick. Their work appears in journals such as Cancer Research, Oncogene, Journal of Biological Chemistry, Proceedings of the National Academy of Sciences and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact